SuperworthNuvectis Pharma EPS NVCT
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- −$1.32
- Latest quarter, Q2 FY26
- −$0.30
- Fiscal year 2025
- −$1.33
Nuvectis Pharma's earnings per share was −$1.32 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.30.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.33 | n/a |
| FY2024 | −$1.10 | n/a |
| FY2023 | −$1.43 | n/a |
| FY2022 | −$1.48 | n/a |
| FY2021 | −$2.96 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.30 | n/a | −$1.32 | |
| Q1 FY26 | −$0.26 | n/a | −$1.32 | |
| Q4 FY25 | −$0.32 | n/a | −$1.33 | |
| Q3 FY25 | −$0.44 | n/a | −$1.36 | |
| Q2 FY25 | −$0.30 | n/a | −$1.16 | |
| Q1 FY25 | −$0.27 | n/a | −$1.12 | |
| Q4 FY24 | −$0.35 | n/a | −$1.10 | |
| Q3 FY24 | −$0.24 | n/a | −$1.16 | |
| Q2 FY24 | −$0.26 | n/a | −$1.29 | |
| Q1 FY24 | −$0.25 | n/a | −$1.41 | |
| Q4 FY23 | −$0.41 | n/a | −$1.43 | |
| Q3 FY23 | −$0.37 | n/a | −$1.48 |
Against its peers
Companies in Drug Manufacturers - General nearest Nuvectis Pharma's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NVCTNuvectis Pharma | −$1.32 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| ABUSArbutus Biopharma | $0.78 | |
| ARVNArvinas | $0.16 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| PCRXPacira BioSciences | $0.35 | |
| Peer median | $0.85 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Nuvectis Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.